Selinexor plus a commercial bispecific antibody for relapsed or refractory multiple myeloma

A Phase II Safety and Efficacy Study of Selinexor in Combination With Bispecific Antibody in Patients With Relapsed/Refractory Multiple Myeloma

This study will test whether adding selinexor to a commercial bispecific antibody helps adults with relapsed or refractory multiple myeloma reach deeper remissions and is safe.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 27 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Duke University (other)
• Drugs / interventions: teclistamab, elranatamab, talquetamab, chimeric antigen receptor
• Locations: 1 site (Durham, North Carolina)
• Trial ID: NCT06822972 on ClinicalTrials.gov

What this trial studies

This Phase 2, single-center study will enroll 27 adults with relapsed or refractory multiple myeloma who are receiving a commercially available bispecific antibody (teclistamab, elranatamab, or talquetamab). Participants will receive selinexor 40 mg alongside their prescribed bispecific antibody dosing for up to 12 months or until disease progression, with follow-up for 24 months. The co-primary objectives are to characterize safety and to measure MRD negativity at 10^-5 at 12 months after bispecific antibody therapy. The trial is powered to detect an increase in MRD negativity from an historical rate of 25% to 50% with 27 patients.

Who should consider this trial

Good fit: Adults (≥18) with relapsed or refractory multiple myeloma who have had at least four prior lines including a proteasome inhibitor, an immunomodulatory agent, and a CD38 antibody, are receiving teclistamab, elranatamab, or talquetamab, and have ECOG ≤2.

Not a fit: Patients not receiving one of the specified bispecific antibodies, those with unresolved CRS/ICANS, poor performance status, or fewer prior therapies are unlikely to qualify or derive benefit from this protocol.

Why it matters

Potential benefit: If successful, the combination could increase the rate of deep (MRD-negative) remissions and potentially prolong responses in heavily pretreated patients.

How similar studies have performed: Bispecific T-cell engager antibodies have shown promising activity in relapsed/refractory multiple myeloma, but combining them with selinexor is relatively novel with limited prior clinical data.

Eligibility criteria

Inclusion Criteria:

1. Age ≥ 18 years old at the time of informed consent.
2. Willing and able to provide written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.
3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
4. A diagnosis of symptomatic multiple myeloma, with relapsed or refractory disease. Patients must have received at least 4 prior lines of therapy. Prior lines of therapy must include a proteasome inhibitor, an immunomodulatory agent, and an CD38 monoclonal antibody, and may include treatment with BCMA antibody conjugates or BCMA directed chimeric antigen receptor (CAR) T cell therapy.
5. All patients must meet criteria for and will receive teclistamab, elranatamab or talquetamab, as per approved label dosing.
6. Patients who have had CRS/ICANS from bispecific antibody must have complete resolution of CRS/ICANS before initiation of SEL
7. Measurable disease as defined by at least one of the following:

   * Serum monoclonal (M) protein ≥1.0 g/dl by protein electrophoresis
   * \>200 mg of M protein in the urine on 24 hour electrophoresis
   * Serum immunoglobulin free light chain ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
   * Measurable plasmacytoma
8. Adequate hepatic function measured on labs collected within 28 days of C1D1:

   * Total bilirubin \<1.5 × upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \<3 × ULN), and
   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) normal to \<2.5 × ULN.
9. Adequate renal function measured on labs collected within 28 days of C1D1. Adequacy will be determined by creatinine clearance with values of ≥ 15 mL/min meeting inclusion criteria. Creatinine Clearance will be calculated using the Cockcroft and Gault formula \[(140 - Age) x Mass (kg)/ (72 x creatinine mg/dL); multiply by 0.85 if female\] (Cockcroft 1976).
10. Adequate hematopoietic function measured on labs collected within 7 days of C1D1:

    * Absolute neutrophil count ≥1500/mm3
    * Hemoglobin ≥8.5 g/dL
    * Platelet count ≥100,000/mm3 (patients for whom \<50% of bone marrow nucleated cells are plasma cells) or ≥50,000/mm3 (patients for whom ≥50% of bone marrow nucleated cells are plasma cells)
    * Note 1: Patients receiving hematopoietic growth factor support, including erythropoietin, darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and platelet stimulators (e.g., eltrombopag, romiplostim, interleukin-11) are eligible.
    * Note 2: Patients must have at least a 1-week interval from the last platelet transfusion prior to the Screening platelet assessment. However, patients may receive RBC and/or platelet transfusions as clinically indicated per institutional guidelines during the study.
11. Patients who are able to become pregnant must have a negative serum pregnancy test at screening.
12. All patients who could become pregnant or could father a child must use highly effective methods of contraception throughout the study and for 5 months following the last dose of study treatment. Highly effective methods of contraception are listed in Section 9.3.1.
13. Female patients must agree not to donate egg during the study treatment period and/or up to 90 days after the last dose of Selinexor. Male patients must agree not to donate sperm during the study treatment period and/or up to 90 days after the last dose of Selinexor.

Exclusion Criteria:

1. Patients who have received and were refractory to selinexor or another specific inhibitor of nuclear exporter (SINE) compound previously. Note: Patients who were exposed to selinexor or another SINE compound but were not refractory are eligible.
2. Patients with any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection) that is likely to interfere with study procedures.
3. Patients with any uncontrolled active infection requiring medical or surgical management within 1 week prior to Cycle 1 Day 1 (C1D1). Note: Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are eligible.
4. Females who are pregnant or breastfeeding females.
5. Patients with active, unstable cardiovascular function, as indicated by the presence of any of the following:

   * Symptomatic ischemia
   * Uncontrolled clinically significant conduction abnormalities (e.g., ventricular tachycardia on anti-arrhythmics); note: patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block are eligible
   * Congestive heart failure of New York Heart Association Class ≥3
   * Known left ventricular ejection fraction \<40%
   * Myocardial infarction within 3 months prior to C1D1.
6. Patients with well controlled chronic viral hepatitis and/or Human Immunodeficiency Virus can be considered for the study if they meet any of the following conditions:

   * Patients with active hepatitis B virus (Hep B) who have been on antiviral therapy for hepatitis B for \>8 weeks and whose viral load is \<100 IU/ml prior to first dose of trial treatment
   * Patients with treated or untreated hepatitis C virus (HCV) and successfully treated and "cured" HCV
   * Patients with Human Immunodeficiency Virus (HIV) who have CD4+ T-cell counts ≥ 350 cells/µL and no history of AIDS-defining opportunistic infections in the last year
7. Patients who still have any grade of CRS/ICANS at 5 (± 2) days of administration of the first full treatment dose of bispecific antibody treatment will be excluded
8. Patients with any active gastrointestinal dysfunction interfering with their ability to swallow tablets or any active gastrointestinal dysfunction that could interfere with absorption of study treatment
9. Patients who are unable or unwilling to take supportive medications such as anti-nausea and anti anorexia agents as recommended by the NCCN CPGO for antiemesis and anorexia/cachexia (palliative care)
10. Patients who have any psychiatric, medical, or other condition that, in the opinion of the investigator, could interfere with treatment, compliance, or the ability to give informed consent.
11. Patients with contraindication to any of the required concomitant drugs or supportive treatments
12. Patients unwilling or unable to comply with the protocol

Where this trial is running

Durham, North Carolina

• Duke University Health System — Durham, North Carolina, United States (RECRUITING)

Study contacts

• Principal investigator: Yubin Kang, MD — Duke Health
• Study coordinator: Lauren Hill

Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory